JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Abstract
The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed. Janus kinase-inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19 patients due to their proven efficacy against diseases with excessive cytokine release and their direct antiviral ability against viruses including coronaviruses, respectively.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 11, 2021
- Source ID
- 10.1186/s12879-020-05730-z
Entities
People
- Andre P. Rebaza
- Avi J. Cohen
- Charles S Dela Cruz
- James Vanchieri
- Lokesh Sharma
- Lucas Walz
- Martin D. Slade
Organizations
- United States Department of Defense
- United States Department of Veterans Affairs